NP Blog / Endocrine & Metabolic / A1c Targets by Patient: Age, Comorbidity, Hypoglycemia Risk and What the Exam Expects

A1c Targets by Patient: Age, Comorbidity, Hypoglycemia Risk and What the Exam Expects

By Ala Alrashaeideh, Founder, NPPace·9 min read·Updated 2026-11-02

The short answer

For most nonpregnant adults the ADA 2026 goal is an A1c below 7 percent. A lower goal such as below 6.5 percent fits healthy patients who can reach it without hypoglycemia, and a less stringent goal such as below 8 percent fits patients with frailty, cognitive or functional limits, severe comorbidity or high hypoglycemia risk. In older adults in very complex or poor health, no A1c number drives treatment: the aim is to avoid hypoglycemia and symptomatic hyperglycemia.

The ADA Standards of Care in Diabetes 2026 set a default A1c goal of below 7 percent for most nonpregnant adults, and then move that number for the patient in front of you. A healthy adult who can get there safely may aim lower, such as below 6.5 percent. An adult with frailty, cognitive or functional limitation, severe comorbidity or high hypoglycemia risk gets a less stringent goal, such as below 8 percent, and an older adult in very complex or poor health is not treated to an A1c number at all.

Board items on glycemic goals almost never ask for the default number alone. They describe a patient and ask whether the current regimen is too much, too little or about right. This article walks through the variables that move the target, the older adult categories, hypoglycemia, CGM metrics, the situations where A1c misleads and the monitoring schedule.

The three anchor goals

The 2026 Standards express the goals in three recommendations:

Default (Recommendation 6.3a): A1c below 7 percent for many nonpregnant adults, without significant hypoglycemia.
Tighter (Recommendation 6.4): a lower goal, such as below 6.5 percent, may be appropriate when it can be achieved safely, without hypoglycemia or a heavy treatment burden. The typical patient is younger, with a long life expectancy, short disease duration and no cardiovascular disease, on agents that do not cause hypoglycemia.
Less stringent (Recommendation 6.5): a goal such as below 8 percent may be appropriate for patients with significant cognitive or functional limitations, frailty, severe comorbidities, or for whom the harms of treatment are greater than the benefits.

The governing principle is the same in all three: goals are individualized, revisited over time and set with the patient.

Variables that move the target


Factor	Points toward a tighter goal	Points toward a less stringent goal
Hypoglycemia risk from the regimen	Low (metformin, GLP-1 receptor agonist, SGLT2 inhibitor)	High (insulin, sulfonylurea, meglitinide)
Life expectancy	Long	Limited
Disease duration	Recently diagnosed	Long-standing
Comorbidity	Few or none	Severe, multiple, or advanced vascular complications
Cognitive and functional status	Intact	Impaired, frail, dependent
Resources and support	Good access, engaged, monitors reliably	Limited support, lives alone, cannot recognize lows
Patient preference	Wants tight control and accepts the burden	Prioritizes simplicity and safety

A vignette usually stacks several factors in the same direction. An 83-year-old on insulin with falls and memory loss points entirely toward the less stringent column. A 38-year-old diagnosed last year on metformin points toward the tighter column. When factors conflict, hypoglycemia risk carries the most weight on the exam because it is the harm that is immediate and measurable.

Older adults: the health-status categories

Section 13 of the 2026 Standards sorts older adults by health status rather than age alone.


Health status	Typical features	A1c goal	CGM goal (if used)
Healthy	Few coexisting chronic illnesses, intact cognitive and functional status	Below 7.0 to 7.5%	Time in range 70% or more; time below 70 mg/dL 4% or less
Complex or intermediate	Multiple coexisting chronic illnesses, two or more instrumental ADL impairments, or mild to moderate cognitive impairment	Below 8.0%	Time in range 50% or more; time below 70 mg/dL under 1%
Very complex or poor health	Long-term care, end-stage chronic illness, moderate to severe cognitive impairment, or two or more ADL dependencies	No A1c goal: avoid hypoglycemia and symptomatic hyperglycemia	Not driven by numeric targets

The descriptive features in the second column are the long-standing ADA categories; confirm their exact wording in the current Section 13 table. The goals in the third and fourth columns are from Recommendations 13.7a to 13.7c.

Two older adult recommendations are tested often. First, for patients at high risk of hypoglycemia, deintensify or switch the drugs that cause it (insulin, sulfonylureas, meglitinides). Second, deintensify when the harms or burdens of treatment may outweigh the benefits. Deintensification is an active plan, not a failure of care: it means stopping a sulfonylurea, simplifying a multiple-injection insulin regimen to basal insulin, or moving insulin to a time when a caregiver is present.

Hypoglycemia: the variable that overrides the rest

The ADA classifies hypoglycemia in three levels:


Level	Definition	What it means for the plan
Level 1	Glucose below 70 mg/dL and 54 mg/dL or higher	Alert value; treat and look for a pattern
Level 2	Glucose below 54 mg/dL	Clinically significant; reevaluate the regimen
Level 3	Severe event with altered mental or physical status requiring assistance from another person, at any glucose value	Reevaluate the regimen; prescribe glucagon; review driving safety

Recommendation 6.19 states that one or more episodes of level 2 or level 3 hypoglycemia should prompt reevaluation of the treatment plan. Age 75 or older is listed among the risk factors, with the highest risk in type 2 diabetes in patients taking insulin or insulin secretagogues. Other risk factors that appear in vignettes include CKD, cognitive impairment, hypoglycemia unawareness, alcohol use, missed meals and a recent severe event.

Treatment of a conscious patient with glucose below 70 mg/dL is 15 to 20 g of glucose (glucose is preferred), with a recheck in 15 minutes and repeat treatment if still low, followed by a meal or snack once glucose normalizes. Glucagon is prescribed for anyone at risk of level 2 or 3 hypoglycemia, and family members or caregivers should know how to give it.

Time in range: the CGM version of the goal

The 2026 Standards recommend CGM for adults on insulin, on oral agents that can cause hypoglycemia, or on any regimen where it helps management, and the goals have CGM equivalents:


Metric	Most adults	Older or high-risk adults
Time in range, 70 to 180 mg/dL	More than 70%	More than 50%
Time below 70 mg/dL	Less than 4%	Less than 1%
Time below 54 mg/dL	Less than 1%	Confirm in the current guideline

CGM also exposes nocturnal lows that a normal-looking A1c hides. A patient whose A1c is 6.8 percent with 9 percent of readings below 70 mg/dL is not well controlled.

Pregnancy and youth

Glycemic goals in pregnancy are tighter because the target is fetal outcome. The ADA pregnancy section has long set an A1c goal below 6 percent if it can be achieved without significant hypoglycemia, relaxed to below 7 percent when needed to prevent hypoglycemia (confirm in the current Section 15). Women with preexisting diabetes who plan pregnancy are referred for preconception care. For children and adolescents, the ADA goal is below 7 percent for many patients (confirm in the current Section 14). On an adult primary care exam, the pregnancy number appears mainly as a distractor in a nonpregnant vignette.

When the A1c is not the right number

A1c reflects average glucose over about 3 months, assuming normal red cell lifespan and normal hemoglobin. It misleads with:

Hemoglobin variants (some assays), and conditions with altered red cell turnover such as hemolysis, iron deficiency or recent blood loss.
Transfusion or erythropoietin therapy.
Advanced CKD and dialysis.
Pregnancy, especially the second and third trimesters.
G6PD deficiency and HIV treated with certain antiretrovirals.

In these settings, glucose meter data or CGM guide therapy. A vignette with an A1c of 6.1 percent and fingerstick glucose readings in the 200s is testing this, not good control.

Monitoring frequency

Recommendation 6.2 sets the schedule: assess glycemic status at least twice a year in patients meeting goals, and more often, about every 3 months, in those not at goal, after a treatment change, or with frequent or severe hypoglycemia or hyperglycemia. Recommendation 9.15 adds that intensification or deintensification for adults not meeting individualized goals should not be delayed. A patient whose A1c has been above goal at three consecutive visits with no change to therapy represents clinical inertia, which the exam treats as an error.

Matching the goal to action

Once the goal is set, the A1c leads to one of three decisions:

Above the individualized goal: intensify, choosing agents with low hypoglycemia risk where possible and checking adherence, technique and lifestyle first.
Within the goal: continue, and confirm there is no hypoglycemia hiding behind the number.
Below the goal in a patient on insulin or a secretagogue with high hypoglycemia risk: deintensify. Stop or reduce the sulfonylurea first, then simplify insulin.

Patient and caregiver education

Explain the personal target and why it differs from a friend's or relative's goal.
Teach recognition of hypoglycemia (shakiness, sweating, confusion, behavior change) and the rule of 15 to 20 g of glucose with a recheck in 15 minutes.
Caregivers of older adults should know that confusion or a fall can be a low, and how to give glucagon.
Check glucose before driving when taking insulin or a sulfonylurea.
Report any low below 54 mg/dL or any episode that needed help, because the plan should change after it.

How the exam tests this

The overtreated older adult. A frail patient with dementia on glipizide with an A1c of 6.3 percent and a recent fall. The answer is to stop the sulfonylurea, not to praise the number.
The default number in the wrong patient. Options that push an 84-year-old in a nursing facility to below 7 percent are wrong; options that accept 8.5 percent in a healthy 45-year-old are also wrong.
Pregnancy numbers in a nonpregnant vignette. Below 6 percent is a pregnancy goal, not a general adult goal.
Ignoring discordant data. A normal A1c with high glucose readings in a patient on dialysis or with recent transfusion means the A1c is unreliable.
Missing the reevaluation trigger. One level 2 or level 3 event is enough to change the plan; options that wait for a pattern are distractors.
Inertia. Rechecking in 6 months when the A1c is above goal and nothing has changed is not the expected answer.

Practice question

An 81-year-old woman with type 2 diabetes is brought to the clinic by her daughter, who now manages her medications. She has moderate Alzheimer dementia and needs help with bathing and dressing. She takes metformin 500 mg twice daily and glyburide 5 mg daily. Last week she was found confused and sweaty at home; a fingerstick glucose was 48 mg/dL and she recovered after juice. Her A1c is 6.4 percent and eGFR is 52 mL/min/1.73 m2. Which of the following is the most appropriate management?

A. Continue the current regimen because the A1c is at goal
B. Discontinue glyburide and set glycemic goals around avoiding hypoglycemia and symptomatic hyperglycemia
C. Replace glyburide with glipizide 5 mg daily
D. Discontinue metformin because of her kidney function

Answer: B. Moderate dementia with dependence in basic ADLs places her in the very complex or poor health category, where treatment aims to avoid hypoglycemia and symptomatic hyperglycemia rather than reach an A1c number, and a level 2 event requires reevaluation of the regimen. Continuing (A) treats the A1c as the goal and ignores a dangerous low. Switching to glipizide (C) keeps a hypoglycemia-causing sulfonylurea in a patient who just had a severe low. Stopping metformin (D) is not required at eGFR 52, and metformin carries little hypoglycemia risk on its own.

Key points

Default A1c goal is below 7 percent; below 6.5 percent only when safe; below 8 percent for frailty, cognitive or functional limits, severe comorbidity or high hypoglycemia risk.
Older adults: healthy below 7.0 to 7.5 percent, complex or intermediate below 8.0 percent, very complex or poor health without an A1c goal.
One level 2 (below 54 mg/dL) or level 3 hypoglycemic event requires reevaluation of the regimen.
Deintensify insulin, sulfonylureas and meglitinides in patients at high hypoglycemia risk; an A1c below goal can be the problem.
CGM goals for most adults: time in range above 70 percent, below 70 mg/dL under 4 percent, below 54 mg/dL under 1 percent.
Check A1c at least twice a year at goal and about every 3 months when not at goal or after a change.
Distrust the A1c when red cell turnover or hemoglobin is abnormal, and treat by glucose data.

Related NPPace guides

Frequently asked questions

Common follow-up questions on Endocrine & Metabolic.

Is an A1c of 6.2 percent always a good result?

Not when the patient is frail or takes insulin or a sulfonylurea. An A1c well below the individualized goal in a high-risk older adult is a signal to deintensify, because the harm of hypoglycemia outweighs any benefit from tighter control.

How often should A1c be checked?

At least twice a year in patients meeting their goals, and about every 3 months when they are not at goal, after a treatment change or with frequent hypoglycemia or hyperglycemia.

What CGM numbers correspond to an A1c below 7 percent?

For most adults the ADA pairs it with time in range (70 to 180 mg/dL) above 70 percent, time below 70 mg/dL under 4 percent and time below 54 mg/dL under 1 percent. Older or high-risk adults aim for time in range above 50 percent and time below 70 mg/dL under 1 percent.

When is the A1c itself unreliable?

When red cell turnover or hemoglobin structure is altered, for example hemoglobin variants, anemia, recent blood loss or transfusion, erythropoietin therapy, advanced CKD and pregnancy. Glucose monitoring or CGM then guides therapy.

Sources and references

American Diabetes Association Professional Practice Committee. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes 2026. Diabetes Care. 2026. https://doi.org/10.2337/dc26-S006
American Diabetes Association Professional Practice Committee. 13. Older Adults: Standards of Care in Diabetes 2026. Diabetes Care. 2026. https://doi.org/10.2337/dc26-S013
American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes 2026. Diabetes Care. 2026. https://doi.org/10.2337/dc26-S009
American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes 2026. Diabetes Care. 2026. https://doi.org/10.2337/dc26-S002
Guideline Central. 2026 ADA Diabetes Standards of Medical Care Clinical Guideline Summary. 2026. https://www.guidelinecentral.com/guideline/14119/

Put this into practice

FNP and AGNP board questions written as primary-care cases, with guideline-based explanations, for the AANP and ANCC exams. Create a free account and pick your track.

Create Free Account →